UCB Receives U.S. FDA Approval for 320 mg Single-Injection Device Presentations of BIMZELX® (bimekizumab-bkzx)
U.S. Leadership Team Taco van Tiel Taco van Tiel Head of U.S. Jaime Davis Jaime Davis Head of U.S. Legal Michele Ehler Michele Ehler Head of U.S. Talent Patty Fritz Patty Fritz Head of U.S. Corporate Affairs & Sustainability James Hlavenka James Hlavenka Head of U.S. Ethics and Business Integrity Chris McNeal Chris McNeal Head of U.S. Immunology Kim Moran Kim Moran Head of U.S. Rare Disease Todd Peterson Todd Peterson Head of U.S. Epilepsy and Rare Syndromes Tonja Pitts Tonja Pitts Head of U.S. Insights to Impact Jane Thompson Jane Thompson Head of U.S. Market Access EXECUTIVE COMMITTEE UCB IN THE U.S. LATEST NEWS